000151055 001__ 151055
000151055 005__ 20251017144633.0
000151055 0247_ $$2doi$$a10.3390/jpm12050747
000151055 0248_ $$2sideral$$a129152
000151055 037__ $$aART-2022-129152
000151055 041__ $$aeng
000151055 100__ $$aSalido, Eduardo
000151055 245__ $$aTargeting HIF-1a Function in Cancer through the Chaperone Action of NQO1: Implications of Genetic Diversity of NQO1
000151055 260__ $$c2022
000151055 5060_ $$aAccess copy available to the general public$$fUnrestricted
000151055 5203_ $$aHIF-1a is a master regulator of oxygen homeostasis involved in different stages of cancer development. Thus, HIF-1a inhibition represents an interesting target for anti-cancer therapy. It was recently shown that the HIF-1a interaction with NQO1 inhibits proteasomal degradation of the former, thus suggesting that targeting the stability and/or function of NQO1 could lead to the destabilization of HIF-1a as a therapeutic approach. Since the molecular interactions of NQO1 with HIF-1a are beginning to be unraveled, in this review we discuss: (1) Structure–function relationships of HIF-1a; (2) our current knowledge on the intracellular functions and stability of NQO1; (3) the pharmacological modulation of NQO1 by small ligands regarding function and stability; (4) the potential effects of genetic variability of NQO1 in HIF-1a levels and function; (5) the molecular determinants of NQO1 as a chaperone of many different proteins including cancer-associated factors such as HIF-1a, p53 and p73a. This knowledge is then further discussed in the context of potentially targeting the intracellular stability of HIF-1a by acting on its chaperone, NQO1. This could result in novel anti-cancer therapies, always considering that the substantial genetic variability in NQO1 would likely result in different phenotypic responses among individuals.
000151055 536__ $$9info:eu-repo/grantAgreement/ES/AEI/PID2019-110900GB-I00$$9info:eu-repo/grantAgreement/ES/DGA-FEDER/E35-20R
000151055 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000151055 590__ $$a3.4$$b2022
000151055 591__ $$aMEDICINE, GENERAL & INTERNAL$$b67 / 169 = 0.396$$c2022$$dQ2$$eT2
000151055 591__ $$aHEALTH CARE SCIENCES & SERVICES$$b42 / 107 = 0.393$$c2022$$dQ2$$eT2
000151055 592__ $$a0.665$$b2022
000151055 593__ $$aMedicine (miscellaneous)$$c2022$$dQ2
000151055 594__ $$a2.6$$b2022
000151055 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000151055 700__ $$aTimson, David J.
000151055 700__ $$aBetancor-Fernández, Isabel
000151055 700__ $$aPalomino-Morales, Rogelio
000151055 700__ $$0(orcid)0000-0002-6649-9153$$aAnoz-Carbonell, Ernesto
000151055 700__ $$aPacheco-García, Juan Luis
000151055 700__ $$0(orcid)0000-0001-8743-0182$$aMedina, Milagros$$uUniversidad de Zaragoza
000151055 700__ $$aPey, Ángel L.
000151055 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000151055 773__ $$g12, 5 (2022), [28 pp.]$$pJ. pers. med.$$tJournal of Personalized Medicine$$x2075-4426
000151055 8564_ $$s3788439$$uhttps://zaguan.unizar.es/record/151055/files/texto_completo.pdf$$yVersión publicada
000151055 8564_ $$s2790685$$uhttps://zaguan.unizar.es/record/151055/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000151055 909CO $$ooai:zaguan.unizar.es:151055$$particulos$$pdriver
000151055 951__ $$a2025-10-17-14:27:35
000151055 980__ $$aARTICLE